• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Risedronate for prevention and treatment of osteoporosis in postmenopausal women.
【24h】

Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

机译：利塞膦酸钠用于预防和治疗绝经后妇女的骨质疏松症。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Risedronate sodium is an N-containing bisphosphonate that has been approved for the prevention and treatment of osteoporosis in postmenopausal women. An increase in the rate of bone remodelling is a regular feature of oestrogen withdrawal during the menopausal transition, but excessive remodelling leads to bone fragility. Risedronate and similar compounds reduce the rate of bone remodelling by suppressing the action of osteoclasts. The antifracture efficacy of risedronate is impressive. In large clinical trials of postmenopausal women with osteoporosis-related fracture(s) at entry, the risk of incident vertebral and non-vertebral fractures was reduced by approximately 40%. In older women at risk for hip fracture, incident hip fractures were also reduced by approximately 40%. Antifracture efficacy develops within the first 6 months, and treatment has been followed for as long as 5 years without deleterious effects on bone. We await reports of experience with risedronate in 'real-world' cases of greater complexity (i.e., in patients with co-morbidities and medications that would have excluded them from published clinical trials).
机译：利塞膦酸钠是一种含氮的双膦酸盐，已被批准用于预防和治疗绝经后妇女的骨质疏松症。骨重塑率的增加是绝经期过渡期雌激素戒断的常规特征，但过度重塑会导致骨脆性。 Riseronate和类似化合物通过抑制破骨细胞的作用来降低骨重塑的速率。利塞膦酸盐的抗骨折功效令人印象深刻。在入院时患有骨质疏松症相关骨折的绝经后妇女的大型临床试验中，发生椎骨和非椎骨骨折的风险降低了约40％。在有髋部骨折风险的老年妇女中，发生的髋部骨折也减少了约40％。抗骨折功效在最初的6个月内得到发展，并且已经进行了长达5年的治疗，而对骨骼没有有害影响。我们正在等待有关在复杂性更高的``现实世界''案例中（例如，患有合并症和药物的患者，可能将其排除在已发表的临床试验之外）的利塞膦酸盐治疗经验报告。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号